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Summary 
To investigate the functional roles of individual HLA-DR residues in T cell recognition, transfectants 
expressing wild-type or mutant DR(o~, B1"0401) molecules with single amino acid substitutions 
at 14 polymorphic positions of the DI~1"0401 chain or 19 positions of the DRo~ chain were 
used as antigen-presenting cells for five T  cell clones specific for the influenza hemagglutinin 
peptide, HA307-19. Of the six polymorphic positions in the DRB floor that were examined, 
mutations at only two positions eliminated T  cell recognition: positions 13 (four clones) and 
28 (one clone). In contrast, individual mutations at DRB positions 70, 71, 78, and 86 on the 
oe helix eliminated recognition by each of the dones, and mutations at positions 74 and 67 eliminated 
recognition by four and two clones, respectively. Most of the DRol mutations had minimal or 
no effect on most of the clones, although one clone was very sensitive to changes in the DRo~ 
chain, with loss of recognition in response to 10 mutants. Mutants that abrogated recognition 
by all of the clones were assessed for peptide binding, and only the B86 mutation drastically 
decreased peptide binding. Single amino acid substitutions at polymorphic positions in the central 
part of the DRB c~ helix disrupted T cell recognition much more frequently than substitutions 
in the floor, suggesting that DRB residues on the ol helix make relatively greater contributions 
than those in the floor to the ability of the DR(oe,~l*0401) molecule to present HA307-19. 
The data indicate that DRq8 residues  13, 70, 71, 74, and 78, which are located in pocket 4 of 
the peptide binding site  in the crystal  structure of the DR1  molecule, exert  a  major  and 
disproportionate influence on the outcome of T cell recognition, compared with other polymorphic 
residues. 
T 
he MHC molecules on the cell surface have evolved the 
remarkable capacity to bind and present to T lympho- 
cytes an extremely large number of structurally diverse pep- 
tides. Recognition of the appropriate peptide-class II com- 
plexes by the antigen-specific  TCR leads to CD4 + T  cell 
proliferation and a cascade of cellular immune responses. HLA 
class II molecules are highly polymorphic, and this structural 
polymorphism determines the distinct peptide-binding and 
antigen presentation characteristics  of each molecule. How- 
ever, the functional roles of individual residues in HLA class 
II molecules in peptide binding and T cell recognition have 
not been dearly defined. Elucidation of the ways in which 
class II residues interact with peptides and TCR may have 
important implications for understanding the function of the 
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immune system, as well as for the treatment ofimmunologi- 
cally mediated diseases. 
Considerable progress has been made in the understanding 
of the structure of HLA class II molecules and the nature 
of class II-peptide interactions in recent years. Based on the 
crystal structure of HLA-A2 and the homologies between 
class I and II molecules, Brown et al. (1) proposed a struc- 
tural model for class II molecules.  The HLA-DR1  three- 
dimensional structure indicates that this model is generally 
accurate (2). In the initial DR1 crystal structure, the first do- 
mains of the ot and B chains form an antigen-binding groove 
composed of two c~ helices that rise above a floor of B strands. 
Importantly, the side chains of most of the polymorphic 
residues in the three hypervariable regions of the DRB chain 
point in toward the groove, where peptides are bound. At 
the level of the peptide molecule, several studies have defined 
residues crucial for binding to MHC and/or T cell recogni- 
tion (3-6).  Based on the relative spacing of such residues, 
it was concluded that peptide antigens were most likely to 
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obtained by use of a combination of site-directed mutagen- 
esis,  direct  peptide-binding  studies,  and  single amino  acid 
replacements in the peptide,  Krieger et al.  (7)  described a 
model of peptide--class  II interactions in which the peptide 
was bound in an NH2 to COOH orientation and in a fully 
extended conformation. The recently solved structure of the 
complex of DR1 and an antigenic peptide of influenza hemag- 
glutinin (HA307-19) permits precise identification of the DR1 
residues that make contacts with this peptide (8) and indi- 
cates that the model of peptide-class II interactions proposed 
by Krieger et al. (7) is remarkably accurate. However, struc- 
tural data alone cannot define the relative functional impor- 
tance of each DR residue whose side chain contacts peptide 
or is positioned such that it may interact with TCR. Further 
progress in the understanding of the contribution of individual 
class II residues to peptide binding  and T  cell recognition 
will require integration  of functional data from analysis  of 
class II mutants  with  structural  data from additional  class 
II-peptide complexes and, perhaps, class II-peptide-TCR com- 
plexes. Although future determination of the structure of class 
II-peptide-TCR complexes may permit resolution of some 
of the  current  ambiguities  in  the  interpretation  of struc- 
ture-function studies, the structure of the trimolecular com- 
plex alone will not define the relative functional importance 
of individual class II residues that contact TCR or peptide. 
In many previous studies of the structure-function  rela- 
tionships of MHC class II molecules, mutagenesis has been 
used to produce individual or multiple interallelic substitu- 
tions between two closely related alleles that differ by a few 
residues (9-11). For example, the contributions of individual 
I-El3 residues to T cell responses were investigated by making 
mutations in El3  k, Eli b, and E/~  s at positions 29, 72, 75, and 
79, which correspond to DRB positions 28, 71, 74, and 78 
(1, 9). Other studies analyzed the effects of mutations at larger 
numbers of positions in class II ot (12) or B (7,  13) chains. 
However, these previous studies still did not address the func- 
tional roles of other residues predicted to contribute to pep- 
tide binding and T  cell recognition,  because only a limited 
set of substitutions was analyzed and, most importantly, the 
contribution of only a single chain (or or/3) was investigated. 
In the current  study, we have taken a broader approach by 
selecting for mutation  14 positions in  the/3  chain  and  19 
positions in the c~ chain of a DR molecule. We selected for 
mutagenesis all those polymorphic DIL/3 positions that were 
predicted in the class II model to point into the peptide-binding 
groove: positions 9,  11, 13, 28, 30, and 37 in the floor and 
positions 57, 60, 67, 70, 71, 74, 78, and 86 on the c~ helix 
(1). We wondered whether the residue present at each of these 
polymorphic positions in the floor and o~ helix was equally 
likely to play an important  role in T  cell recognition of the 
class II-peptide complex. The Dlkot positions analyzed in- 
cluded 6 in the floor and 7 on the ot helix that were predicted 
in the model to point into the binding groove, and 6 on outer 
loops. This mutagenesis approach permits assessment of the 
functional involvement of individual residues,  as well as com- 
parisons of the contributions of residues in the floor versus 
those on the ol helix of each chain. 
The objective of this study was to analyze the involvement 
of 33 individual  residues of the DR(or,131*0401)  molecule 
in T cell recognition and peptide binding. Importantly, this 
molecule is associated with susceptibility to the development 
and severity of rheumatoid arthritis (14-16). Transfectants  ex- 
pressing wild-type or mutant DR(c~,fll*0401) molecules were 
used as APC for five DR(c~,fll*0401)-restricted T cell clones 
specific for HA307-19, a peptide of influenza hemagglutinin 
that can be bound and presented by multiple DR molecules. 
We found that  mutations  at  six of eight positions on the 
fl chain c~ helix, but only two of six positions in the fl chain 
floor, affected T cell recognition. The ot chain mutations had 
minimal or no effects on most of the clones.  The data dem- 
onstrate  that  T  cell  recognition  of the  DR(cr,fll*0401)- 
HA307-19 complex is much more sensitive to substitutions 
on the fl chain ol helix than  to those in the fl chain floor. 
In addition,  DtLt3  residues  13,  70,  71,  74,  and  78,  which 
are located in pocket 4 in the DR1 molecule (8), exert a major 
and disproportionate influence on T  cell recognition of the 
peptide/DR  complex,  compared  with  other polymorphic 
residues. 
Materials and Methods 
cDNA  Clones and Site-directed Mutagenesis.  cDNA clones en- 
coding full-length HLA-DR c~ or B chains in the pcD expression 
vector  (17) were  used: DRA  (18), DRBI*0401,  DRBI*0402, 
DRBI*0403,  DRBI*0404,  DRBI*0405  (obtained  from  Peter 
Gregersen, North Shore University Hospital, Manhasset, NY) (19), 
and DRBI*0101  (American  Type Culture  Collection  [ATCC], 
Rockville, MD) (20). Site-directed mutagenesis of the DRA and 
DR(B1*0401) cDNAs was performed by the PCR overlap exten- 
sion method (21), and the mutants were sequenced to confirm the 
presence of the mutation  and the absence of miscorporation  as 
described (22). 
Transfection and mAbs.  The mutant DRA or DRB cDNA was 
cotransfected with the complementary wild-type DRB or DRA 
cDNA into the DAP.3 subclone of class II- murine L fibroblasts 
as described (23). The transfectants were cloned by limiting dilu- 
tion or flow cytometric sorting, and cloned transfectants were used 
in T cell proliferation and peptide-binding assays. The class II ex- 
pression levels of the transfectants were monitored by FACS  |  anal- 
ysis (Becton Dickinson & Co., Mountain View, CA) with the anti- 
DR mAb L243 (ATCC) (24), or HU-20 (obtained from Akemi 
Wakisaka, Hokkaido University School of Medicine, Sapporo, Japan) 
(25) for those transfectants whose L243 epitope was disrupted by 
the Dlkot mutations  (26) (Table 1). Antibody binding  to selected 
transfectants was also analyzed with the polymorphic anti-DR mAb 
AC.BM.50  (Dominique  Charron,  Institut  Biomedical des Cor- 
deliers, Paris, France) (27), 21r5 (Michelle Letarte, Hospital for Sick 
Children, Toronto, Canada) (28), and the anti-DR4 mAb GS359- 
13F10 (Susan Radka, Bristol-Myers  Squibb Pharmaceutical Research 
Institute,  Seattle, WA) (29). 
T  Cell  Clones and  T  Cell Proliferation Assay.  Five influenza 
hemagglutinin  peptide HA307-19-specific T cell clones were iso- 
lated from PBL of three DR(c~d31*0401)  § individuals as described 
(7). Briefly, HA307-19-specific and DR(ot,Bl*0401)-restricted  T 
cell lines were established by incubating  the PBL in vitro with 
HA307-19, and expanded with recombinant Ib2 (Genzyme Corp., 
Cambridge, MA). The T cell lines were cloned by limiting  dilu- 
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assays, 2  x  104 irradiated  L transfectants  were incubated  with 
HA307-19 at concentrations  of 0.01, 0.1, and 1.0/~M  in round- 
bottom 96-well plates at 37~  in 5% CO2 overnight,  and then 
the superuatant was removed before adding 5  x  104 quiescent T 
cells. After incubation  for 2 d, the culture  was pulsed with 0.5 
/~Ci [3H]TdR (DuPont,  Boston, MA) per well. After further in- 
cubation for 16 h, the cells were harvested by use of a cell harvester 
(Tomtec, Orange,  CT), and the [3H]TdR incorporation  was de- 
termined by liquid scintillation counting by use of a scintillation 
counter (LKB-WaUac  model 1205 Betaplate; LKB-Pharmacia, Fin- 
land). DAP.3 cells transfected with the neomycin resistance gene 
only (DAPneo) were used as a negative control.  Transfectants ex- 
pressing wild-type DIL(c~,BI*0401) at  high  (Dw4H), medium 
(Dw4M), and low (Dw4L) levels were used as positive controls. 
Peptide-binding Assay.  HA307-19 (PKYVKQNTLKLAT)  was 
synthesized in the Department of Medicinal Chemistry, G. D. Searle 
& Co., with an automated peptide synthesizer (Applied Biosystems, 
Inc., Foster City, CA) with standard Boc-amino acid coupling pro- 
tocols (30). The peptide resin was biotinylated by coupling with 
succinimidyl-6-(biotinamido)  hexanoate  (Pierce Chemical  Co., 
Rockford, IL) and purified by reverse-phase HPLC (Delta-Pak C-18; 
Waters, Milford, MA). The composition of the peptide was verified 
by amino acid analysis and fast-atom bombardment mass spectro- 
scopy. For the peptide-binding  assay (31), 3  x  10  s transfectants 
were incubated with 10/~M biotinylated HA307-19 (B-HA) ~  over- 
night at 37~  in a V-bottom 96-well tissue culture plate, washed 
three times with 1% PBS 0.02% BSA sodium azide, and incubated 
with streptavidin-quantum  red conjugate  (Sigma Chemical Co., 
St. Louis, MO) for 30 rain. After three additional washes, the cells 
were analyzed on a FACScan  |  (Becton Dickinson & Co.). The bio- 
tinylated gp41 582-595 (B-GP) from HIV-1 envelope  protein, which 
is presented by the DPw4.2 molecule (32), was used as a negative 
control.  The data were collected and analyzed to obtain the mean 
channel fluorescence (MCF) on a linear scale for each sample by 
use of data analysis programs (Lysis II; Becton Dickinson & Co.). 
The MCF of the biotinylated peptide binding was normalized to 
that of L243 binding as a measure of DR expression level on each 
transfectant. 
Dw4 Model.  To better correlate the mutation data with three- 
dimensional structure, a homology model of DP431"0401 was con- 
structed by use of the coordinates (provided by Jerry Brown, Har- 
vard University,  Cambridge,  MA) of the 3.2-A  x-ray structure 
of DRBI*0101 (2) as the template. The two protein sequences differ 
at 17 positions;  there are no residue insertions or deletions. The 
DRBI*0401 substitutions were imposed on the DR/31"0101 tem- 
plate by following the procedures of Summers and Karplus (33, 
34) using the program CHARMM (35) and parameter sets detailed 
elsewhere (35-38). The resulting model structure is geometrically, 
statistically, and energetically indistinguishable from highly refined 
protein crystal structures solved  at high resolution. The figures of the 
model were created with software (lnsightlI  version 2.20; Biosym 
Technologies, San Diego, CA) on a workstation (IRIS 4D/310GTX; 
Silicon Graphics, Mountain  View, CA). 
Results 
To analyze the contributions of individual residues in the 
DR(/31"0401) and DRcx chains to recognition of HA307-19 
t Abbreviations used in this paper: B-GP, B-HA, biotinylated gp41 582-595 
and HA307-19, respectively; MCF, mean channel fluorescence. 
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by DR(olj31"0401)-restricted T  cell clones, 23 site-specific 
mutants of the DR(•1"0401)  chain and 22 mutants of the 
DRo~ chain  were produced  and  expressed with  the  com- 
plementary wild-type DRol or DR(/31"0401) chain on trans- 
fectants that were used as APC in T  cell proliferation assays. 
The DP43 positions selected for mutagenesis were predicted 
in the class II model (1) to point into the peptide-binding 
groove. Importantly, most of these predictions were confirmed 
by the DR1 structures.  In the DR1 crystal structures (2, 8) 
and our DR(c~,~I*0401) structural model, DI~3 residues 9, 
11,  13,  28,  30,  and 37 are located in one half of the floor 
of the antigen-binding groove with their side chains pointing 
up, and residues 57, 60, 67, 70, 71, 74, 78, and 86 are located 
on the ol helix with their side chains pointing either in to- 
ward the groove (residues 57, 60, 71, 74, 78, and 86) or up 
and in (residues 67 and 70) (Fig.  1 A). Residues in the floor 
with their side chains pointing up are potential peptide con- 
tact residues, whereas residues on the c~ helixes may be pep- 
tide and/or TCR contact residues, depending on the orien- 
tation  of their  side chains,  the  angle  at  which  the  TCR 
approaches  the  class  II-peptide  complex,  and  the  bound 
peptide. 
The substitution strategy was to change the residue in the 
DR(/31"0401) chain to the residue found at the corresponding 
positions in other DR alleles (Table 1). In most cases, two 
substitutions were made at each position of DR(f31*0401). 
The first substitution at each position in the floor, plus those 
at positions 60 and 78 on the c~ helix, were made by changing 
the residue to the corresponding  residue found in DR(/31"0701). 
For the substitutions at positions 57, 67, 70, 71, 74, and 86 
on the c~ helix,  the residue of DR(31"0401)  was changed 
to that found in other DR4 subtypes. To gain a broader pic- 
ture of the functional roles of each residue, we also constructed 
a  second  set  of substitutions  with  physical  and  chemical 
changes different than those of the first set of substitutions. 
For example, the DR/3 position 28 mutations include both 
the conservative D --~ E substitution from DR(/31"0701) and 
the nonconservative  D --~ H substitution from DR(/31"09011). 
Expression  of the/330  Y  ~  R  and/357  D  ~  V  mutants 
was not  obtained. 
DRot chain mutations were made at residues 7, 9, 11, 22, 
24, and 31, which are located in the other half of the floor 
of the groove with their side chains pointing up, and at other 
DtLo~ residues located on the outer loops with their side chains 
pointing up (residues 15, 18, and 39), away (residues 36 and 
42), or down (residue 19) (8). Additional DRcx residues mu- 
tated are located on the ol helix with their side chains pointing 
into the groove (residues 65 and 72), up (residue 49), up and 
in (residue 55), away (residues 47 and 50), or down toward 
the floor (residue 66). The DRc~ residues were changed to 
the residues found at the corresponding positions in the I-Ecr 
DPc~,  DQol,  or I-Ac~ chain,  as described (39). 
The five HA307-19-specific T cell dones used in this study 
were isolated from three DR(c~,Bl*0401)-positive donors, and 
each proliferated in response to HA307-19 presented by the 
DR(o~,/31"0401) transfectant. Because of the DtL/3 sequence 
similarities among the DR4 subtypes and DR1, we first in- 
vestigated the restriction patterns of these clones by use of Table  1.  Site-l~'rected  Mutagenesis of DRot and DR(~I *0401) Chains 
DR(BI*0401)  chain  DRc~ chain 
Position  Mutation  MCF ratio*  Position  Mutation  MCF ratio 
9  E  "~ W  1.34  7  I  ~  S  0.66 
9  E  "~ Q  1.42  9  Q  --~ G  0.85 
11  V  ~  G  0.88  11  E  ~  A  0.84 
11  V  ~  S  1.45  15  N  ~  L  0.93 
13  H  "-~ Y  1.80  18  Q  ~  K  1.50 
13  H  ~  F  0.95  19  S  --~ R  1.91 
28  D  "~ E  1.82  22  F  --~ Y  1.23 
28  D  -~ H  1.02  24  F  --~ H  0.84 
30  Y  "~ L  1.91  31  I  ~  E  0.75 
37  Y  ~  F  0.81  36  M  -'~ I  1.52 
37  Y  ~  S  1.42  39  K  -'~ S  1.26 
57  D  -~ S  1.46  42  V  ~  I  1.70 
60  Y  --~ S  1.16  47  E  --~ L  2.18 
67  L  --~ I  0.70  47  E  ~  R  1.39 
67  L  -~ F  1.12  49  G  -" A  1.64 
70  Q  -'~ D  1.40  50  R  "-~ K  1.52 
70  Q  ~  R  0.79  55  E  -~ D  1.75 
71  K  ~  E  0.84  65  V  -~ I  1.84 
71  K  ~  R  1.50  66  D  -~ V  1.27 
74  A  "~ E  1.73  66  D  "~ L  1.41 
74  A  "-~ Q  0.84  66  D  ~  R  0.89 
78  Y  "-~ V  0.79  72  I  ~  V  0.91 
86  G  -~ V  1.26  Dw4H  WT  1.38 
Dw4H*  WT  1.14  Dw4M  WT  (441) 
Dw4M  WT  (570)  Dw4L  WT  0.51 
Dw4L  WT  0.44 
* The ratio of averaged mean channel fluorescence (MCF) of Dw4H, Dw4L,  and all of the mutants  to that of Dw4M. The MCF for Dw4M  is 
given in parentheses. Data are averaged from at least three experiments. 
Transfectants with high (H), medium (M), and low (L) expression levels of wild-type (WT) DR (~,~1"0401). 
transfectants  expressing  other DR  molecules.  The DR31 
chains  associated  with  the  five  major  DR4  subtypes 
(DIL81*0401, 0402, 0403, 0404, and 0405) differ only among 
residues on the c~ helix, namely, 357, 367, 370, 371, 374, 
and 386 (Table 2). In the first domain, DR(31"0101) differs 
from DR(31"0401) at polymorphic positions in the floor and 
only at 371 on the a  helix. Of the five clones, three are re- 
stricted only by DR(ol,31"0401), and the other two are also 
cross-reactive with DR(a,31*0405). 
T cell responses to the panel of DR(31"0401) mutant trans- 
fectants are shown in Fig. 2. Overall,  the T cell clones dis- 
played five distinct reactivity patterns. Among the DR(31"0401) 
mutations made in the floor, both position 13 mutations abol- 
ished or significantly reduced the recognition of HA307-19 
by four clones. The 328  D  "~ H  mutation also drastically 
decreased recognition by clone 33C6.6 only, whereas the con- 
servative D  -" E mutation did not significantly affect T  cell 
recognition by any of the clones. The responses of the five 
clones to the 3 position 9, 11, 30, and 37 mutants were com- 
parable  to the responses  to the wild-type transfectants. 
The mutations on the ot helix of DR(31"0401) affected 
T cell recognition of HA307-19 much more frequently, com- 
pared with  those in the floor. At least one substitution at 
positions 70,  71,  78,  and 86 abolished recognition by all 
five of the T  cell clones, and at least one of the position 74 
mutants eliminated recognition by four of the clones. The 
370 Q  -~ R  and B86 G  --" V  mutations had the broadest 
effects, resulting in abrogation of recognition by all clones. 
In contrast,  the 370  Q  ~  D  mutant  presented e~ciently 
to two  clones.  The conservative 371  K  "-- R  substitution 
induced significant proliferation by two  of the clones, but 
abrogated or markedly reduced responses by the other three, 
918  Functional Roles of DR(o~,BI*0401) Residues in T Cell Recognition Figure  1.  Structural model of the DR(ot,ffl*0401) molecul~ The carbon 
atoms of residue 8D,/5'70, B71, ~ff/4, and 878 are shown in bhe-green, 
828 in blue, ~  in magenta, and 886, ot24, and or31 in yellow. The rest 
of the carbon atoms of the 8  chain is shown in pink, and the ot chain 
in dark blue. Oxygen atoms are shown in red, nitrogen in blue, and hydrogen 
in white. For visual simplicity,  only polar hydrogens are shown. (A) Top 
view of the ot helices and binding groove as a ribbon diagram showing 
the locations of the residues  that were substituted. The ribbon of the ot 
chain is shown in dark blue, and the 8  chain is shown in pink. (B) To 
facilitate  visualization of the inner wall of the 8  chain ot helix and the 
adjacent  floor,  the structure has been rotated around an axis that runs 
through the length of the binding groove such that the ot domain is ro- 
tated toward the viewer and the 8 domain is rotated away from the viewer. 
The highlighted residues are labeled in C. (C) Magnified view of the orien- 
tation shown in B. 826 located at the bottom of this pocket is also shown. 
Table  2.  HLA-DR  Restriction of T  Cell  Clones Specific for HA307-19 
DR~  residues*  T  cell  recognition pattern* 
HI,A-DR  57  67  70  71  74  86  JB/Y/A2  JB/12B/A10  3BC6.6  KM1HA27  KM1HA28 
DR(c~,~l*0401)  D  L  Q  K  A  G  +  +  +  +  + 
DR(ot,~l*0402  -  I  D  E  -  V  ..... 
DR(or,B1*0403)  -  -  -  K  E  V  ..... 
Dg(a,Bl*0404)  -  -  -  g  -  V  ..... 
DR(c~,/~1"0405)  S  -  -  R  -  -  -  +  +  -  - 
DR(ot,/~l*0101)  -  -  -  R  ....... 
* Only residues  in the third hypervariable region and different among the alleles listed are shown. 
* T  cell proliferation assays were done at peptide concentrations of 0.01, 0.1, and 1.0 ttM. For DR(or,81*0401),  +  indicates robust proliferation, 
similar to that shown in Fig. 2 (Dw4H).  For DR(or,81*0405),  +  denotes that the dose-response curve resembles  that of the prototype molecule, 
DR(or,81*0401).  -  indicates flat dose-response curve comparable to the negative control shown in Fig.  2  (DAPneo). HA307-319: 
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Figure  2.  Effects of the DR(31,0401) mutations 
on T  cell recognition of HA307-19.  The levels of 
3H[TdR] incorporation in T cell proliferation  assays 
are shown as counts per minute on the y axis. Substi- 
tutions and/or the positions of the DR(31-0401) chain 
are shown on the x  axis. DAPneo,  a class II-  and 
G418-resistant  L transfectant,  was used  as negative 
control.  Transfectants  expressing  wild-type  DR 
(0e,31-0401) at high (Dw4H), medium (Dw4M), and 
low (Dw4L) levels were used  as positive controls. 
whereas the nonconservative 371 K ~  E eliminated prolifer- 
ation by four clones. The abilities of clones JB/12B/A10 and 
3BC6.6 to recognize the 371 K ~  R mutant correlate well 
with  the  cross-reactivities  of  these  clones  with  DR(o~, 
31"0405),  which has arginine  at  371  (Table 2).  The 374 
A ~  E and A --* Q  mutations eliminated  the response by 
four and two clones, respectively. Only clone KM1HA28 gave 
a minimal  response at the highest  peptide concentration  to 
the B78 mutant.  At 367, the conservative L -* I substitu- 
tion reduced  proliferation  by only one clone,  whereas  the 
L --," F substitution eliminated  recognition by two clones. 
These data indicate that DR3 o~ helix residues 70, 71, 74, 
78, and 86 play crucial roles in the presentation of HA307-19. 
T cell responses to the DRo~ mutants are shown in Fig. 
3. Overall, the five clones displayed five different reaction pat- 
terns with the DRo~ mutant panel. Recognition of HA307-19 
by JB/Y/A2 and KM1HA28 was abrogated  by one of the 
DRoL chain mutations,  and none of the DRc~ chain muta- 
tions abrogated recognition by JB/12B/A10. The single mu- 
tations at DRo~ positions 22, 24, and 31 and one of the mul- 
tiple mutations at positions 47 and 66 abrogated or significantly 
decreased recognition by KM1HA27. The ell1 mutation was 
the only one that abrogated recognition by  JB/Y/A2. In con- 
trast  to the four clones described above, clone 3BC6.6 was 
much more sensitive to substitutions in the DRoe chain; many 
of the DR~ mutations reproducibly affected the recognition 
by this  clone.  Among the DRo~ mutants,  the position 24 
and 31 mutations abrogated or significantly decreased recog- 
nition by three clones and shifted the dose-response curve 
of the remaining two clones to higher peptide concentrations. 
In contrast  to the DR(B1*0401)  chain,  each of the muta- 
tions made in the floor residues of Dlq.el affected recognition 
of HA307-19 by at least one T  cell clone. 
The elimination  of recognition by some mutations in the 
DR.o~ and DR.(31"0401)  chains may be due to inability  of 
these mutants to bind the peptide. Substitutions at DIq.B po- 
sitions 13, 70, 71, 74, 78, and 86 and at DRo~ positions  24 
and 31 caused major effects on the recognition of HA307-19 
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Figure 3.  Effects  of the DRt~ mutations on T cell 
recognition of HA307-19. Refer to Fig. 2 for legend. 
by multiple T  cell clones. In contrast  to the B70 Q  -* R, 
78 Y -* R, 78 Y -* V, and 86 G -~ V mutations that affected 
recognition by each of the five clones, the other mutants still 
presented the peptide efficiently to at least one T  cell clone, 
documenting that these mutants were still able to bind the 
peptide. Binding of B-HA to the DR(B1*0401) 70 Q -~ K, 
78 Y  --~ V, and 86 G "-- V  mutants  was analyzed by flow 
cytometry (Fig. 4). Other mutants with major effects on rec- 
ognition were also included for comparison.  B-GP, which 
is a DP-binding peptide (32), and the DR(a, B1"0404) trans- 
fectant, which is a poor HA307-19 binder (40), were used 
as negative controls. The B86 G --- V mutation was the only 
one that almost abolished the binding of HA307-19 to the 
DR(a,/~1"0401)  molecule.  Interestingly,  the c~24 F --~ H 
substitution increased binding of the negative control pep- 
tide gp41 582-595 to the DR molecule, providing additional 
evidence that c~24 interacts with peptides. The findings that 
most mutations did not prevent peptide binding are consis- 
tent with the DK1/HA peptide structure, in which hydrogen 
bonds between 12 nonpolymorphic and 3 polymorphic class 
II  residues  and  main-chain  atoms  of  the  peptide  make 
significant  contributions  to binding  of the peptide (8).  In 
this context, it is interesting to note that our mutations at 
er  and/371,  which form such hydrogen bonds with 
the peptide in the DR1  structure,  did not prevent peptide 
binding.  The results of the T cell proliferation and peptide- 
binding  studies are  summarized  in  Table  3. 
Because most of the mutants  still presented the peptide 
efficiently to at least one T cell clone, it is unlikely that these 
mutants have gross conformational changes.  To address  the 
possibility that the broad effects on T cell recognition caused 
by the mutations at DR(/31*0401) positions 70, 78, and 86 
were due to gross alteration of the DR(or,/31*0401) confor- 
mation,  these mutants,  as well as the DRB position 13, 71, 
and 74 mutants and the DRo~ position 24 and 31 mutants, 
were analyzed with four polymorphic anti-DR mAbs. The 
HU-20,  AC.BM.50,  21r5,  and GS359-13F10 mAbs detect 
four distinct epitopes on DR4 molecules (41-43). All of the 
921  Fu et al. 0.7 
A 
0.6- 
0.4- 
0.3- 
0.1 
0,  ,  Dw]~14  ~  ,  ,  ,  0.5  4E 
,.~  0.4 
I~  0.3 
I  i 
0"I  0 
l  l  I  I  I  I  I 
Dw4H  Dw4M  Dwl4  B,H13F B,Y78V fl,G86V ct,F24H ct,I31E 
￿9  B-HA/B-L243  []  B-GP/B-L243 
Wild-~Vpu  or mutant t~ts 
Figure  4.  The binding of B-HA to transfcctants expressing the wild- 
type DR.(o~,~I*0401) and the mutants. The MCF of a biotinylated pep- 
tide binding is normalized to that of L243 binding,  which is shown on 
the y axis. The transfectants expressing DR(or,B1*0404) and B-GP were 
used as negative controls. 
mutants still bound each of the polymorphic anti-DR mAbs 
at levels comparable to the wild-type DR(ol,~l*0401)  trans- 
fectant (data not shown), indicating that the mutations did 
not cause gross conformational changes in the DR(c~,BI*0401) 
molecule. 
Discussion 
In these studies, single amino acid substitutions in the floor 
of DIL81*0401 affected T cell recognition much less frequently 
than substitutions on the oc helix, despite the fact that similar 
aUelic substitution strategies were used for the floor and c~ 
helix. This discrepancy was surprising, based on the distri- 
bution of presumably functionally important polymorphic 
residue in both the ~ strands and the c~ helix of class II mole- 
cules. Similar results, with frequent effects on T cell recogni- 
tion by substitutions at multiple positions on the DIL8 chain 
helix and infrequent effects by substitutions in the floor, 
were observed in studies of other DR molecules and antigen 
systems that used the same DRB mutagenesis strategy:  DR1- 
restricted  recognition  of  pertussis  toxin  (13)  and  DR7- 
restricted  recognition  of rabies  antigen and HA307-19  (7, 
22).  It is important to note that we have obtained similar 
results with DRB mutants and T cells that recognize a promis- 
cuous peptide, such as HA307-19,  and a monogamous pep- 
tide,  such as p30-42  of pertussis toxin.  However,  in these 
earlier  studies,  only one  substitution was made  at ]3 floor 
positions 9,  11,  13,  28,  30,  and 37.  Because the nature of 
the substitution may affect the results, it is possible that the 
Table  3.  Summary of Effects of DR(c~r  *0401) Mutants on  T  Cell Proliferation and Peptide Binding* 
T  cell proliferation  s 
Position  Accessibility*  Mutation  JB/Y/A2  JB/12B/A10  3BC6.6  KMIHA27  KMIHA28  Peptide bindingn 
fl13  p  H  "~  F  -  _+  -  -  +  + 
fi13  H  "*  Y  ....  +  + 
~70  p,t  Q  ""  D  -  -  +  -  +  + 
~70  Q  --~  p,  .....  + 
B71  p,t  K  "*  E  ....  +  + 
/371  K  ""  R  _+  +  +  -  -  nd 
fi74  p  A  "~  E  ....  +  + 
fl74  A  "-~  Q  -  +  +  -  +  nd 
B78  p  Y  "*  V  ....  _+  + 
~86  p  G  ---  v  ...... 
a24  p  F  --~  H  +  +  -  -  +  + 
o~31  p  I  "*E  +  _+  -  -  -  + 
* Data  shown in reduced form  are from experiments  shown in Figs.  2-4. 
* The accessibility of a DR  residue to peptide and TCR contacts is based on the DR1/HA307-19 structure (8). p, peptide contact; t, potential TCR 
contact. 
S  +,  Proliferation levels at peptide concentration  1.0/~M >30%  of that with wild-type Dw4H;  _+,  proliferation <30%;  -,  proliferation close to 
that with the negative  control (DAPneo). 
II  +,  HA307-319 binding levels >30%  of that with the wild-type Dw4H;  -,  binding levels close  to that with the negative controls. 
rid, not done. 
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the floor in these previous studies was because the substitu- 
tions were too conservative. To address this possibility, two 
substitutions  with distinct size and/or charge characteristics 
were introduced at five of the six positions in the floor of 
DR31"0401.  However, only mutations at 3  floor residues 
13 and 28 were found to affect T  cell recognition. 
What is the basis for the finding that T cell recognition 
was not affected by substitutions  in the DR31"0401 chain 
at four of the six polymorphic residues whose side chains 
point up from the floor into the peptide binding groove? 
One possibility is that the substitutions  at positions  9,  11, 
30, and 37, which affected recognition by none of the clones, 
resulted in less substantial size, charge, and/or chemical char- 
acteristic changes than those made at positions  13, 28, 67, 
70, 71, 74, 78, and 86, which eliminated T cell recognition 
by one or more clones. This explanation seems unlikely be- 
cause at least one substitution at each of positions 9, 11, 30, 
and 37 represented a very significant change. For example, 
the position 9 E ~  W  substitution replaced the negatively 
charged side chain of glutamic acid with the bulkier,  non- 
polar side chain of tryptophan, and the position  11 V ~  S 
and V --~ G substitutions  replaced the nonpolar side chain 
of valine  with the polar side chain of serine  or the much smaller 
glycine. The absence of effects by the position 9, 11, 30, and 
37 substitutions  are in contrast to the marked effect of the 
highly conservative c~ helix 371 K --- R substitution on three 
clones. Another possibility is that the side chains of residues 
9, 11, 30, and 37 in the wild-type chain and/or the substituted 
residues do not contact the peptide.  The absence of effects 
by substitutions  at DK31"0401  residues 30 and 37 is consis- 
tent with the findings that these residues are not in contact 
with either the endogenous peptides or HA307-19 in the DR1 
structures  (2,  8) and suggests that the same is true when 
HA307-19 is bound to DR4. In contrast,  however, the side 
chains of DR31"0101  residues 9 and 11 are in contact with 
the HA307-19 in the DR1 structure.  The third possibility 
is that DR31"0401 residues 9,  11, 30, and/or 37 do make 
contacts with bound HA307-19, but the substitutions at these 
positions have little or no functional consequences because 
these interactions have no effect on the determinants recog- 
nized by the TCR. 
Despite attempts to gather evidence to the contrary,  we 
have consistently found the surprising result that T cell rec- 
ognition of multiple DR-peptide complexes is more sensi- 
tive to interallelic substitutions  on the ot helix than to analo- 
gous substitutions  in the floor, suggesting that, as a group, 
residues at polymorphic positions  in the floor make lesser 
contributions to T cell recognition of a specific  peptide than 
those on the ot helix. These results underscore the necessity 
to complement structural data with in-depth functional anal- 
yses, in order to fully appreciate the relative functional roles 
of the different interactions revealed  by crystallographic anal- 
ysis. Polymorphic 3 residues in the floor are clearly impor- 
tant in the function of class II molecules. We envision that, 
in many cases, their contributions are operative more in de- 
termining the range of peptides that can be bound by a given 
molecule than in influencing the outcome of recognition of 
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a peptide  that has already been selected for binding, as in 
our analytical system. However, an example in which a class 
II B chain residue in the floor determined peptide binding 
has been reported (9). 
What are the mechanisms by which the substitutions  at 
DR(B1*0401) positions  13, 28, 67, 70, 71, 74, 78, and 86 
eliminated T  cell recognition?  Depending on the location 
of  the residue, the possibilities include (a) disruption of  a critical 
TCR contact,  (b) prevention of peptide binding, (c) change 
in the conformation of the bound peptide, or (d) change in 
the conformation of the DR(oe,BI*0401) molecule. Each of 
the mutants except 386  G  --- V  still bound the peptide, 
documenting that most residues other than 386 do not indi- 
viduaUy  determine whether the peptide does or does not bind. 
The mutant molecules do not appear to have grossly altered 
conformations,  as judged by the ability of each mutant to 
bind several mAbs and by the fact that each mutant, except 
70 Q -~ R, 71 K -* E, 78 Y "* V, and 86 G -~ V, presented 
antigen efficiently to at least one clone. 
The position 86 mutation probably affected T cell recog- 
nition by causing a marked decrease in the ability of the mol- 
ecule to bind the peptide. These findings are consistent with 
previous reports showing that the dimorphism at position 
86 of the DR3 chain is critical in peptide binding and T 
cell recognition (7, 40, 44-46).  On the other hand, the nat- 
ural dimorphism at 3  position  86 does not seem to be the 
only factor that determines the binding of HA307-19 to DR 
molecules. For example, DR(c~,31"1301) and DR(or,31*1401) 
bind HA307-19 at high levels  but have valine at position 86, 
and DR(or,31*09011), which has glycine at position 86, binds 
HA307-19 poorly (47). These data suggest that polymorphic 
residues in other regions,  in addition to several conserved 
residues (8), also contribute to the binding of HA307-19 by 
some molecules. In the DR1/HA307-19 structure, residues 
in a deep pocket in the peptide-binding  site, consisting  of 
386 and c~24, c~31, oe32, o~43, 385,  389,  and 390, contact 
tyrosine 309 of the peptide (8). This pocket is likely to be 
similar between DR(or,31*0101) and DR(or,B1*0401), be- 
cause their sequences in this region are identical.  Interest- 
ingly, mutations at DRc~ positions 24 and 31 had major effects 
on T  cell recognition but not on HA307-19 binding.  Al- 
though these DRoe residues were not essential for HA307-19 
anchoring, they are likely to contribute to the conformation 
of the pocket and/or the anchored peptide. The spatial rela- 
tionships of DR386, c~24, and ot31 are highlighted in Fig. 
1, B and C. 
Residue 370 played a crucial role in recognition by each 
of the clones  studied.  In the DR1/HA307-19  structure, 
DR31"0101  residue 70 glutamine contacts peptide residue 
312 (glutamine)  and is exposed such that it might also in- 
teract with TCR (8). In our DR(ol,31"0401) model, the side 
chain of 370 glutamine points up and in over the peptide- 
binding groove such that it might contact both peptide and 
TCR. In addition,  antibody-binding data suggest that the 
side chain of DR31"0401 residue 70 is solvent accessible; the 
70 Q---D mutation in 31"0401 eliminated binding of two 
mAbs but did not affect binding of several others (48). In 
the initial DR1 structure and our DR(or,31*0401)  model, residue 67 is located at the highest point of the 8  chain a 
helix, making it a prominent feature of the top surface of 
the molecule. In contrast, residue ~67 contacts peptide leu- 
cine 315 and is exposed for possible TCR interaction in the 
DR1/HA307-19 structure. Therefore, DRBI*0401 residues 
67 and 70 likely affected T cell recognition in our studies by 
altering peptide conformation and/or a critical TCR contact. 
The side chains of ~ residues 13, 28, 71, 74, and 78 point 
into the peptide-binding groove in the DR1 structures and 
the Dw4 model (Fig.  1, B and C). The side chains of DR3 
residues 13, 70, 71, 74, and 78, as well as c~9, form a shallow 
pocket, referred to as pocket 4, which is occupied by peptide 
residue 312 glutamine in the DR1/HA307-19 structure (8). 
In addition, DR3 residue 28 makes contact with peptide res- 
idue 315  in  the DR1/HA307-19  structure.  The fact that 
DR31"0401 and 0101 differ only at positions 13 and 71 within 
pocket 4 suggests that the shape of this pocket in DtL81*0401 
is likely to be similar to that found in DRBI*0101.  In the 
DR1/HA307-19  structure (8),  residue 13 is located in the 
floor of the peptide-binding groove below the peptide, indi- 
cating that it is not accessible to TCR contact. The side chains 
of residues 74 and 78 point down toward the peptide-binding 
groove and contact the peptide, but they were not felt to 
be exposed for potential TCR contact (8).  In the context 
of these structural data,  our findings that  substitutions at 
DIL81*0401  positions 13, 74, and 78 eliminated recognition 
by multiple clones, whereas peptide binding was preserved, 
indicate that these mutations most likely affected T cell rec- 
ognition by altering the conformation of the bound peptide 
instead of by altering TCR contacts. Because 871 is also ex- 
posed in the DR1/HA307-19 structure, substitutions at this 
position may affect T cell recognition by altering peptide con- 
formation and/or a TCR contact. The likelihood that the 
mutations at all or some of DR3l*0401 residues 13, 28, 70, 
71, 74, and 78 affected T cell recognition by altering peptide 
conformation are consistent with recent studies that indicate 
that TCR recognition of the class II-peptide complex is pri- 
marily determined by the TCR CDR3-peptide interaction 
(49). Taken together, the functional and structural data indi- 
cate that DR~1"0401 residues 13, 70, 71, 74, and 78 in pocket 
4 contribute to a functional unit that has a disproportion- 
ately large influence on the outcome of T cell recognition, 
compared with the other polymorphic positions. In the con- 
text of the functional data, the proximity and arrangement 
of residues 13, 70, 71, 74, and 78 in the Dw4 model are im- 
pressive  (Fig.  1, B and C). 
The DRa mutations had minimal or no effects on three 
of the clones, an intermediate effect on one clone, and wide- 
spread,  significant effects on one clone. The DRa substitu- 
tions at positions 22, 42, 49, 50, 55, 65, and 72 are relatively 
conservative, which may contribute to the lack of effects on 
T  cell recognition with these DRa mutants. Mutations at 
oe24 and 31, which, as noted above,  are located in the 886 
pocket, affected the largest number of clones. The sensitivity 
of clone 3BC6.6 to 11 mutations scattered throughout DRc~ 
is noteworthy, especially in contrast to the reactivity patterns 
of the other four clones to the DRa mutants and the local- 
ized effects of the DR(~/1"0401) mutants on 3BC6.6. Prolifer- 
ation of 3BC6.6 was eliminated or reduced by each of the 
6 mutations in the floor of DRop.  Because these mutations 
did not prevent peptide binding, they probably caused changes 
in peptide conformation to which 3BC6.6 is exquisitely sen- 
sitive but which are tolerated by most of the other clones. 
Interestingly, mutations at ol positions 15,  18, and 39 that 
affected recognition by this clone are located on outer loops 
away from the peptide-binding groove, raising the possibility 
that the area of contact of the TCR with class II may, in 
some cases, extend beyond the o~ helices. 
Our findings that substitutions at multiple positions on 
the DR8 chain ol helix frequently eliminated T cell recogni- 
tion are consistent with previous studies in murine (11, 50, 
51) and human (52,  53) systems that found that 8  chain c~ 
helix residues,  especially those in the central portion of the 
helix, are important for recognition. However, the current 
study adds the important perspective that these DIL8 chain 
oe helix residues influence T  cell recognition far more fre- 
quently than other highly polymorphic residues in the same 
chain. These residues,  especially those in pocket 4,  appear 
to be uniquely positioned to influence features of the class 
II-peptide complex that are required for T cell recognition 
by affecting peptide conformation and/or providing critical 
TCR contacts. Influences on peptide conformation by these 
B chain a  helix residues may more frequently affect T  cell 
recognition than those on the floor because the conforma- 
tional effects are more pronounced at the surface of the pep- 
tide contacted by TCR. 
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